Chen W, Chen M, Barak LS. Development of small molecules targeting the Wnt pathway for the treatment of colon cancer: a high-throughput screening approach. Am J Physiol Gastrointest Liver Physiol 299: G293-G300, 2010. First published May 27, 2010; doi:10.1152/ajpgi.00005.2010.-Wnt proteins play major roles in development and differentiation, and abnormalities in their regulation are believed to contribute to the formation of many cancers, including colorectal malignancies. As a result, there has been an interest in identifying small molecule inhibitors of Wnt signaling as tool compounds for research or as precursors to new generations of anticancer drugs. Advancements in robotic technology along with reductions in the costs of equipment, chemical libraries, and information handling have made high-throughput drug discovery programs possible in an academic setting. In this minireview we discuss the most plausible protein targets for inhibiting Wnt signaling in colon cancer therapy, list small molecule Wnt inhibitors that have been identified through recent drug discovery efforts, and provide our laboratory's strategy for identifying novel Wnt signaling antagonists using highthroughput screening. In particular, we summarize the results of a screen of over 1,200 drug and druglike compounds we recently completed in which niclosamide was identified as a Wnt pathway antagonist.Wnt; Frizzled; -catenin; receptor; dishevelled; niclosamide; screening; stem cells SYSTEMATIC PROGRAMS OF DRUG DISCOVERY, once confined primarily to the pharmaceutical industry, are now becoming commonplace in university research programs. The transfer of moderate-to large-scale drug screening capabilities to academic laboratories has been facilitated by recent reductions in the cost of automated screening equipment, compound libraries, and information technology. The identification of small molecule regulators of stem cell signaling associated with cancer development is an area that can benefit greatly as a result of academic screening programs. Presently, there are no small molecules approved by the FDA for the targeted therapy of colon cancer despite its prevalence in the adult population. Wnt signaling appears to be one of the important molecular mechanisms underlying colon cancers, and this has spurred a search for small molecule inhibitors of Wnt pathway proteins. In this minireview we will present a high-throughput screening (HTS) strategy for identifying Wnt pathway signaling antagonists for use in colorectal cancer research and the treatment of colon cancers.
Colon Cancer and Targeted TherapiesColorectal cancers are the third most common forms of cancer and the third leading cause of cancer deaths in the United States, and their incidence has remained relatively unchanged (25). In 2008 there were an estimated 149,000 new cases of colorectal cancer diagnosed and 49,960 deaths in the US (22). Small molecule drugs for treating noncancerous diseases of the gastrointestinal tract form one of the largest targeted drug therapy markets; in 2003...